Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis

Table 3 Subgroup analysis of the prognostic role of SII for PFS/bRFS in patients with prostate cancer

Subgroup factors	No. of studies	No. of patients	Effects model	HR (95% CI)	p	Heterogeneity I² (%) Ph
Total	4	6578	Random	2.49 (1.30–4.77)	0.006	89.8	< 0.001
Region
Asian	3	539	Random	3.31 (1.14–9.59)	0.027	89.9	< 0.001
Non-Asian	1	6039	-	1.34 (1.15–1.56)	< 0.001	-	--
Sample size
< 200	2	248	Random	2.89 (0.61–13.79)	0.183	93.4	< 0.001
≥ 200	2	6330	Random	2.34 (0.71–7.69)	0.160	91.2	0.001
Metastatic status
mCRPC	2	248	Random	2.89 (0.61–13.79)	0.183	93.4	< 0.001
Nonmetastatic	2	6330	Random	2.34 (0.71–7.69)	0.160	91.2	0.001
Cutoff value
< 600	2	395	Fixed	5.45 (3.33–8.92)	< 0.001	0	0.452
≥ 600	2	6183	Fixed	1.34 (1.17–1.54)	< 0.001	0	1.000
Study center
Single center	3	539	Random	3.31 (1.14–9.59)	0.027	89.9	< 0.001
Multicenter	1	6039	-	1.34 (1.15–1.56)	< 0.001	-	-
Treatment
Hormone therapy + chemotherapy	1	104	-	6.60 (3.27–13.30)	< 0.001	-	-
Radical prostatectomy	2	6330	Random	2.34 (0.71–7.69)	0.160	91.2	0.001
Radium-223/chemotherapy	1	144	-	1.34 (0.91–1.98)	0.140	-	-

PFS progression-free survival, SII systemic immune-inflammation index, mCRPC metastatic castration-resistant prostate cancer

ISSN: 1477-7819